1. Home
  2. LMRI vs IMTX Comparison

LMRI vs IMTX Comparison

Compare LMRI & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lumexa Imaging Holdings Inc. Common Stock

LMRI

Lumexa Imaging Holdings Inc. Common Stock

N/A

Current Price

$11.72

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

IMTX

Immatics N.V.

N/A

Current Price

$9.32

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LMRI
IMTX
Founded
2018
N/A
Country
United States
Germany
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.3B
IPO Year
2025
2020

Fundamental Metrics

Financial Performance
Metric
LMRI
IMTX
Price
$11.72
$9.32
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
6
Target Price
$20.75
$19.00
AVG Volume (30 Days)
453.7K
564.8K
Earning Date
05-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.05
N/A
Revenue
N/A
N/A
Revenue This Year
$6.35
N/A
Revenue Next Year
$5.61
$25.91
P/E Ratio
$235.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.45
$5.67
52 Week High
$19.45
$12.41

Technical Indicators

Market Signals
Indicator
LMRI
IMTX
Relative Strength Index (RSI) 57.82 54.21
Support Level $10.09 $9.37
Resistance Level $12.81 $10.55
Average True Range (ATR) 0.56 0.44
MACD -0.04 0.05
Stochastic Oscillator 64.31 80.94

Price Performance

Historical Comparison
LMRI
IMTX

About LMRI Lumexa Imaging Holdings Inc. Common Stock

Lumexa Imaging Holdings Inc is a provider of diagnostic imaging services. The company offers a broad range of imaging modalities, including MRI, CT, PET, X-ray, ultrasound, and mammography. Its products and operations are managed and reported in two operating segments: Outpatient Imaging Centers (Outpatient) and Professional Services (Professional). The professional services segment generates revenue from interpreting imaging studies conducted by other parties, mainly hospital imaging departments. The majority of revenue is generated by the Outpatient segment, which performs imaging studies and provides radiologists' interpretations of those studies.

About IMTX Immatics N.V.

Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.

Share on Social Networks: